NCT05678322Active, not recruitingPhase 3
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence. By consensus, a BCR following RP occurs once the PSA \> 0.2 ng/ml/ Biochemical recurrence often develops years prior to clinical evidence of disease recurrence. Early identification of the site(s) of disease recurrence enables early salvage intervention. Men will be eligible for the study at the point in time their post-prostatectomy PSA level first becomes \>0.2 ng/ml. Only those patients with rhPSMA-7.3 (18F) identifiable disease (local, nodal or systemic) will be offered salvage intervention per standard of care. All patients with a negative initial rhPSMA-7.3 (18F) scan will undergo a second scan when the PSA is \> 0,5 ng/ml or one year after the initial PET study. The salvage interventions will be at the discretion of the investigator. The study will compare the diagnostic yield of the first and second rhPSMA-7.3 (18F) studies.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- First submitted
- 28 Dec 2022
- Start date
- 31 Jan 2023
- Primary completion date
- 8 May 2025
- Lead sponsor
- NYU Langone Health
- Diseases
- Prostate cancer
- NCT number
- NCT05678322
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 26
- From 31 Jan 2023 to the primary completion date, 8 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior allergic reaction to rhPSMA-7.3 (18F).
Other
- Any contraindication for MRI imaging.
- Patient refuses rhPSMA-7.3 (18F) PET/MRI.
Who the study is looking for
- Eligible patients will include all men between age 18 -100 years old,-that have had RP, at the first point in time the PSA \> 0.2 ng/ml.
Age in the registry: 18 years to 100 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Smilow Comprehensive Prostate Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
Related publications
- Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy.EJNMMI Rep · 2026 · PMID 42850466
This page is information, not medical advice. Discuss any trial with your doctor.